On Thursday, Feb. 16th, at 7 PM the Harkins Cine Capri will be showing a one-time-only screening of the "Concert for George."

Originally performed at Royal Albert Hall in London, this tribute to the music of George Harrison has been universally acclaimed as one of the best concert films of all time. It features Paul McCartney, Eric Clapton, Ringo Starr, Tom Petty, Billy Preston, Jeff Lynne (lead singer from ELO) and a host of other incredibly talented musicians.

Tickets are $30 tax-deductible dollars each (plus a $1 service charge) with all proceeds going to benefit the Students Supporting Brain Tumor Research (SSBTR). A large portion of the funds this organization raises goes to fund research programs at Phoenix Children's Hospital and the Barrow Neurological Institute.

Seating is limited to 525 and since sales are done via computer it's strictly first come/first serve. To insure than your are part of what promises to be a memorable evening (the largest screen in Arizona and 40,000 amps of sound)CLICK HERE... Purchase movie tickets online.

Liz is a baseball-sized meningoima brain tumor survivor. The 15-minute segment will feature Liz and her family. Also, this is the first time Mystery Diagnosis has ever featured a meningioma brain tumor survivor.

The air dates and times are: January 16--10 p.m.
January 17--1 a.m.
January 22--6 p.m.

Merck & Co., Inc. announced today that the Food and Drug Administration (FDA) has approved EMEND(R) (aprepitant) for use with other antiemetic medicines for the prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, which are likely to cause nausea and vomiting. EMEND, in combination with other antiemetics, is also approved for the prevention of nausea and vomiting caused by initial and repeat courses of highly emetogenic chemotherapy treatments, which are highly likely to cause nausea and vomiting, including high dose cisplatin.

The FDA approval for EMEND is based on the findings of a study published in April 2005 in the Journal of Clinical Oncology (JCO) that enrolled 866 breast cancer patients, of whom 99.5 percent were women. The study compared a regimen including EMEND (EMEND in combination with ondansetron, a 5-HT3 receptor antagonist, and dexamethasone, a corticosteroid, on day 1 followed by EMEND on day 2 and 3) and a standard regimen (ondansetron and dexamethasone on day 1 followed by ondansetron on day 2 and 3).


Results from this study of breast cancer patients who received moderately emetogenic chemotherapy treatments, which are likely to cause nausea and vomiting, showed that a significantly higher proportion of patients treated with the regimen including EMEND in Cycle 1 reported a complete response (defined as no vomiting and no use of other therapies for nausea or vomiting) in the five days after initiation of chemotherapy compared to a standard regimen (51% vs. 42% , p=0.015). The difference between treatment groups was primarily driven by the "No Emesis Endpoint", a principal component of this composite primary endpoint. In addition, a higher proportion of patients receiving the regimen including EMEND in Cycle 1 had a complete response during the acute (0-24 hours) and delayed (25-120 hours) phases compared with patients receiving the standard regimen; however, the treatment group differences failed to reach statistical significance after multiplicity adjustments.

"Patients with cancer are not only facing a serious illness, they also face the possibility of distressing side effects such as nausea and vomiting from their chemotherapy, and breast cancer patients are particularly susceptible to these side effects," said Kelly Pendergrass, M.D., clinical investigator and medical oncologist at the Kansas City Cancer Center. "The good news is that, with this expanded indication, EMEND can now be used with other antiemetics in the wider population of patients receiving moderately emetogenic chemotherapy to help prevent these worrisome and challenging side effects before they occur."

The study also showed that more patients receiving EMEND reported minimal or no impact of nausea and vomiting on their daily life (64% vs. 56%).READ